BRAF and Miyoshi myopathy: In a study by Larkin et al.2, the median overall survival among patients with BRAF-mutated MM was longer in the Nivolumab-plus-Ipilimumab group (more than 60.0 months; 95% CI, 50.7 to not reached), the Nivolumab group (45.5 months; 95% CI, 26.4 to not reached) and the Ipilimumab group (24.6 months; 95% CI, 17.9–31.0) compared to patients without BRAF-mutated MM (Nivolumab-plus-Ipilimumab group: 39.1 months; 95% CI, 27.5 to not reached, Nivolumab group: 34.4 months; 95% CI, 24.1–59.2, Ipilimumab group: 18.5 months; 95% CI, 14.1–22.7).